Algernon Pharmaceuticals (TSE:AGN)
:AGN
AGN Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.10
Previous CloseN/A
Volume3.18K
Average Volume (3M)13.80K
Market Cap
C$2.32M
Enterprise ValueC$1.54M
Total Cash (Recent Filing)C$210.03K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding46,499,270
10 Day Avg. Volume14,017
30 Day Avg. Volume13,803
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt materially lowers fixed financial obligations and interest exposure, giving management more runway to prioritize R&D and clinical milestones without immediate debt servicing. This structural strength improves financial flexibility for strategic financing or partnering decisions over the next 2–6 months.
Narrowing Losses And Lower BurnThe material reduction in net loss and improved burn rate signals better cost control or program prioritization, which extends runway and reduces near-term dilution risk. Sustained improvement in operating losses supports execution of clinical programs without immediate emergency financing.
Legacy Marketed Product (NP-120)A marketed legacy product provides a tangible commercialization asset that can generate revenue, be licensed, or support partnerships. This optionality can supply non-dilutive funding or validation pathways, lowering program risk compared with pure pre-revenue discovery-only peers.
Bears Say
Zero Reported RevenueAbsence of recurring commercial revenue means the business lacks self-sustaining cash generation; success hinges on clinical or licensing events. Over a 2–6 month horizon this structural gap keeps reliance on external capital and elevates execution risk until a revenue pathway is established.
Negative Operating & Free Cash FlowConsistent negative operating and free cash flows force ongoing capital raises or asset monetization, increasing dilution risk and potentially slowing development timelines if financing conditions tighten. Sustainable operations require either revenue or persistent external funding.
Equity Erosion & Negative ROEHistorical value erosion and persistent negative ROE reflect cumulative losses and weaken the company's financial cushion. This undermines investor confidence, can constrain partnering leverage, and elevates governance and capital-raising challenges during critical clinical stages.
Algernon Pharmaceuticals News
AGN FAQ
What was Algernon Pharmaceuticals’s price range in the past 12 months?
Algernon Pharmaceuticals lowest stock price was C$0.04 and its highest was C$0.10 in the past 12 months.
What is Algernon Pharmaceuticals’s market cap?
Algernon Pharmaceuticals’s market cap is C$2.32M.
When is Algernon Pharmaceuticals’s upcoming earnings report date?
Algernon Pharmaceuticals’s upcoming earnings report date is May 05, 2026 which is in 30 days.
How were Algernon Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Algernon Pharmaceuticals overvalued?
According to Wall Street analysts Algernon Pharmaceuticals’s price is currently Overvalued.
Does Algernon Pharmaceuticals pay dividends?
Algernon Pharmaceuticals does not currently pay dividends.
What is Algernon Pharmaceuticals’s EPS estimate?
Algernon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Algernon Pharmaceuticals have?
Algernon Pharmaceuticals has 46,499,270 shares outstanding.
What happened to Algernon Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Algernon Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Algernon Pharmaceuticals
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―
Options Prices
Currently, No data available
---